Goldman Sachs Group Inc Arcutis Biotherapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,890,246 shares of ARQT stock, worth $27.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,890,246
Previous 1,103,413
71.31%
Holding current value
$27.9 Million
Previous $17.3 Million
53.57%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding ARQT
# of Institutions
240Shares Held
129MCall Options Held
407KPut Options Held
216K-
Suvretta Capital Management, LLC New York, NY11.5MShares$170 Million5.56% of portfolio
-
Jennison Associates LLC11.1MShares$164 Million0.09% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$158 Million3.47% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$146 Million7.3% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$127 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $887M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...